A Phase 1, Multi-Center, Open-Label, Single-Dose, Parallel-Arm Study to Assess the Minimum Effective Concentration of NVK031 on Pupillary Constriction and Distance Vision in Healthy Volunteers
Latest Information Update: 18 Apr 2022
At a glance
- Drugs NVK 031 (Primary)
- Indications Eye disorders
- Focus Pharmacodynamics
- Sponsors Nevakar
- 05 Apr 2021 New trial record